

## Striving for Consensus: Optimizing the Selection and Sequencing of Therapy for Patients with Relapsed/Refractory Follicular Lymphoma — Other Novel Therapies

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase II ROSEWOOD study evaluating the combination of zanubrutinib and obinutuzumab versus obinutuzumab alone for relapsed/refractory (R/R) follicular lymphoma (FL) previously treated with 2 or more prior regimens reported what major efficacy outcomes?**
  - a. Inferior overall response rate (ORR) and progression-free survival (PFS) with zanubrutinib and obinutuzumab
  - b. No significant difference in ORR or PFS with zanubrutinib and obinutuzumab
  - c. A significant improvement in ORR and PFS with zanubrutinib and obinutuzumab**
- 2. In the FL cohort of the ongoing Phase III MAHOGANY trial, what is the therapeutic intervention that is being compared to lenalidomide and rituximab (R<sup>2</sup>) for R/R FL previously treated with 1 or more prior lines of systemic therapy?**
  - a. Ibrutinib with rituximab
  - b. Zanubrutinib with obinutuzumab**
  - c. Tafasitamab with R<sup>2</sup>
  - d. Loncastuximab tesirine with rituximab
- 3. The Phase III inMIND study of tafasitamab and R<sup>2</sup> versus R<sup>2</sup> alone for R/R FL previously treated with 1 or more prior lines of systemic therapy reported what major efficacy outcome?**
  - a. No significant difference in PFS with tafasitamab and R<sup>2</sup>
  - b. A nonsignificant numerical PFS trend favoring tafasitamab and R<sup>2</sup>
  - c. A statistically significant improvement in PFS with tafasitamab and R<sup>2</sup>**
- 4. What is the mechanism of action of tazemetostat?**
  - a. CD19 inhibitor
  - b. CD20 inhibitor
  - c. EZH2 inhibitor**
  - d. Bruton tyrosine kinase inhibitor
- 5. In the Phase III inMIND study of tafasitamab and R<sup>2</sup> versus R<sup>2</sup> alone for R/R FL previously treated with 1 or more prior lines of systemic therapy, what was the approximate ORR for patients who received tafasitamab and R<sup>2</sup>?**
  - a. 21%
  - b. 45%
  - c. 60%
  - d. 83%**